Piezo Motion Announces Partnership With Motion & Control Sales, Ltd
Piezo Motion’s new partnership with Motion & Control Sales, Ltd will further disrupt the precision motor market with cost-effective automation solutions
LAKEWOOD RANCH, Fla. (February 10, 2022) –– via InvestorWire – Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Motion & Control Sales, Ltd today announce a partnership. Piezo Motion is a developer and leading manufacturer of precision motor technology. Motion & Control Sales, Ltd, based in Ohio, has been a manufacturing representative in the motion control industry for more than 22 years.
Piezo Motion’s unique automation technology will enable Motion & Control Sales, Ltd to provide its customer base with a revolutionary precision motor solution. Motion & Control Sales, Ltd serves Michigan, Indiana, Ohio, Kentucky and western Pennsylvania. Its end customers are in industries such as automotive, aircraft manufacturing, smart conveyor systems, electrically operating industrial/military barriers, industrial ventilation and industrial pumping. Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor that is designed specifically for original equipment manufacturers (OEMs) that require ultimate speed, size and accuracy.
“Piezo Motion is an exciting addition to our motion control partners. With their small size, lightweight and simple design, the Piezo Motion motors will be perfect for the small end of arm tooling,” said Greg Fisher, regional sales representative for Motion & Control Sales. “Also, the micro-pumps are a good fit for OEMs who need to accurately meter fluid materials. Our focus for both products will be on OEMs in the automotive, medical and defense industries.”
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.
“Our unique precision technology and Motion & Control Sales’ extensive relationships in the industry will make our unique technologies available to a broader market,” said Hassan Kotob, chairman and CEO of Brain Scientific. “The partnership with Motion & Control Sales will offer best-of-breed motion products for manufacturers that require precision and performance with an affordable automation solution.”
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time, and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products, or investor relations, please visit brainscientific.com.
About Motion & Control Sales, Ltd
Motion & Control Sales, Ltd. (mncsales.com) has been a motion control partner for more than 22 years. With their vast experience in motion control and industrial control, they can help manufacturers and customers achieve their goals. Their end customers are in such industries as automotive, aircraft manufacturing, packaging, smart conveyor systems, electrically operating industrial/military barriers, industrial ventilation, industrial pumping, and others.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.
Los Angeles, California